The effect of age on methacholine response

doi:10.1016/0091-6749(85)90783-3

Journal of Allergy and Clinical Immunology

Volume 76, Issue 4, October 1985, Pages 609-613

https://doi.org/10.1016/0091-6749(85)90783-3 Get rights and content

Abstract

Bronchial reactivity to inhaled methacholine exists in subjects with asthma but may occur in subjects with allergic rhinitis, chronic lung diseases, and during respiratory infections. In the absence of these factors, we found that age also has a significant effect on the methacholine response. One hundred forty-eight subjects, 5 to 76 years of age, were studied as normal control subjects in a natural history of asthma study. The methacholine response was measured by standard techniques. The analysis demonstrated that age had a significant effect on the methacholine response. In addition to known factors influencing the results of methacholine inhalation, young and older subjects may exhibit bronchial responses that may falsely suggest hyperreactive airway disease.

References (12)

R.G. Townley et al.
Methacholine inhalation challenge studies
J Allergy Clin Immunol
(1979)
R Hopp et al.
Specificity and sensitivity of methacholine inhalation challenge in normal and asthmatic children
J Allergy Clin Immunol
(1984)
G Shapiro et al.
Methacholine bronchial challenge in children
J Allergy Clin Immunol
(1982)
R Townley et al.
Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects
J Allergy Clin Immunol
(1975)
E Juniper et al.
Reproducibility and comparison of responses to inhaled histamine and methacholine
Thorax
(1978)
J Fish et al.
Airway responses in allergic and nonallergic subjects
Am Rev Respir Dis
(1976)

There are more references available in the full text version of this article.

Cited by (161)

Asthma in an aging world
2023, Asthma in the 21st Century: New Research Advances
The aging population is further growing at an increasing rate, and asthma is common in the elderly population. To improve the management of asthma in the entire population, it is crucial to understand the pathophysiology of asthma in the elderly. With increasing age, the structural changes including chest wall rigidity, reduced respiratory muscle strength, and changes in the lung parenchyma occur and immunosenescence appears in both the innate and adaptive immune responses. Asthma in the elderly is often underdiagnosed and undertreated because of impaired cognition, inappropriate medication use, various comorbidities, and polypharmacy. As for treatment, confirming the adherence to treatment, inhalation procedures, and sufficient inspiratory flow rate is important before stepping up the treatment. This chapter discusses the epidemiology and phenotypes of asthma in elderly patients, the structural and biological changes in the airways, and how aging can influence the presentation of asthma, along with problems in diagnosis and management.
Asthma over the Adult Life Course: Gender and Hormonal Influences
2019, Clinics in Chest Medicine
Is aging a “comorbidity” of asthma?
2018, Pulmonary Pharmacology and Therapeutics
The aging population is growing at an unparalleled rate. Asthma is common in the elderly (age over 65 years) and can be more severe with little chance for remission. Asthma in older individuals is often under-diagnosed, misdiagnosed and frequently under-treated. Concomitant medical and psychosocial conditions are more prevalent in the elderly and can obfuscate the presentation of asthma and make it more difficult to assess and manage. While these comorbidities are important in understanding elderly asthma, aging itself can be considered a “comorbidity” since it impacts structural and functional changes in the lung. Structural changes of the aging lung may worsen physiologic function in asthma. The immune system also changes with age, with increased vulnerability to pathogens and differences in airway inflammation, leading to variability in how asthma manifests and responds to treatment. The fact that aging can influence the severity and presentation of asthma along with its diagnosis and management is important for the treating physician to understand. This article will discuss the multitude of factors that justify considering aging as a comorbidity of asthma.
Design, synthesis and H<inf>1</inf>-antihistaminic activity of novel 1-substituted-4-(3-chlorophenyl)-[1,2,4] triazolo [4,3-a] quinazolin-5(4H)-ones
2015, Journal of Saudi Chemical Society
Citation Excerpt :
The real breakthrough of non-sedative antihistamines came in the early eighties of the twentieth century when the discovery of modern antihistamines was found to exhibit potent antihistaminic activity without sleep-inducing effects (Carr and Meyer, 1982). Condensed heterocycles containing a new generation of H1-antihistamines (e.g. loratadine, azelastine and flazelastine) that do not possess the above mentioned pharmacophore for H1-antihistamines gave way for the discovery of many novel antihistamines temelastine and mangostin (Hopp et al., 1985; Chairungsrilerd et al., 1996). Quinazolinones are associated with a wide range of biological and pharmacological activities such as analgesic (Mallareddy and Sattur, 1984), anti-inflammatory (Mallareddy et al., 1987), antifungal (Kumar et al., 1997; Bartroli et al., 1998), antiviral (Mukherji et al., 1980) and antihistaminic activities (Raghuramrao et al., 1986; Devsingh et al., 2001; Raju et al., 1999).
In the present study a series of 1-substituted-4-(3-chlorophenyl)-[1,2,4] triazolo [4,3-a] quinazolin-5(4H)-ones were synthesized and screened for their H₁-antihistaminic activity. The synthesized compounds were characterized by IR, ¹H-NMR, mass spectral data and purity of the compounds was determined by elemental analysis. Antihistaminic activity of the title compounds was evaluated by histamine induced bronchoconstriction method in guinea pigs. Among the series, 4-(3-chlorophenyl)-1-methyl-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (S5) was the most potent with the percentage protection of 69.65% and its potency is comparable to the reference drug chlorpheniramine maleate (70.09% protection). Interestingly the sedative property of compound S5 was found to be negligible (5.36%) when compared to chlorpheniramine maleate (34.92%).
Environmental Determinants of Lung Aging
2014, The Lung: Development, Aging and the Environment: Second Edition
The purpose of this chapter is to review the ways in which environmental factors interact with the aging lung. In earlier chapters we saw that the lung ages in a predictable way in mammals, and that aging involves anatomic, physiologic, and immune correlates. Distinguishing between physiologic aging and the additional effects of environmental factors is difficult. As our knowledge of normal aging is based upon data from populations with different genetic susceptibilities to lung disease, it is difficult to distinguish aging per se from the cumulative effects of environmental insults and genetic susceptibility. In this chapter, we explore the factors that influence the susceptibility of the aging lung to environmental injury and the changes in biologic response to inhaled gases, particulates, and micro-organisms that occur over time. We conclude by discussing several common non-neoplastic diseases that are known to be affected by both age and the environment; chronic bronchitis, emphysema, and asthma.
Methacholine challenge testing: Improved patient comfort with a 2-tiered protocol
2013, Annals of Allergy, Asthma and Immunology
The methacholine challenge test (MCT) is a test of bronchial hyperreactivity used as an aid in the diagnosis of asthma. MCT results are reported as the provocation concentration at which the forced expiratory volume in 1 second (FEV₁) decreases 20% (PC₂₀). The requirement for a 20% or greater decrease in FEV₁ results in precipitous decreases in FEV₁ in some patients.
To improve MCT safety without compromising accuracy.
We performed a retrospective analysis of 879 consecutive MCTs (derivation cohort). A novel protocol for MCT was developed and validated in a cohort of 564 MCTs performed in a second institution.
In comparison with a PC₂₀ cutoff of less than 8 mg/mL, a provocation concentration at which the FEV₁ decreases 10% (PC₁₀) cutoff of 1 mg/mL or less has a sensitivity of 86%, a specificity of 98%, a positive predictive value (PPV) of 97%, and a negative predictive value (NPV) of 91%. We propose a novel 2-tiered protocol for MCT. If the PC₁₀ is 1 mg/mL or less, bronchial hyperreactivity is present; if the PC₁₀ is greater than 1 mg/mL, the test is continued until the provocative concentration is 8 mg/mL or a 20% decrease in FEV₁ is achieved. Compared with the standard protocol, the proposed protocol has a sensitivity, specificity, PPV, NPV, and overall accuracy of 100%, 98%, 97.6%, 100%, and 99%, respectively. The modified protocol would have enabled us to avoid 26 of 42 cases (62%) in which a 40% or greater decrease in FEV₁ occurred and would save 0.65 dose for every MCT performed. The 2-tiered protocol performed well in the validation cohort; sensitivity, specificity, PPV, NPV, and overall accuracy were 100%, 98%, 87%, 100%, and 98%, respectively.
The proposed 2-tiered protocol is accurate, saves time, and avoids precipitous decreases in FEV₁.

View all citing articles on Scopus

View full text

Original articleThe effect of age on methacholine response

Abstract

J Allergy Clin Immunol

J Allergy Clin Immunol

J Allergy Clin Immunol

J Allergy Clin Immunol

Reproducibility and comparison of responses to inhaled histamine and methacholine

Thorax

Airway responses in allergic and nonallergic subjects

Am Rev Respir Dis

Original article
The effect of age on methacholine response